study (ClinicalTrials.gov identifier: NCT01336634 ). 5 , 6 Common adverse events (AEs) affecting >30% of patients receiving this combination treatment include pyrexia, chills, fatigue, peripheral edema, nausea/vomiting, diarrhea, abdominal pain
Search Results
Unusual Adverse Events in a Patient With BRAF-Mutated Non–Small Cell Lung Cancer Treated With BRAF/MEK Inhibition
Rohan Maniar, Stephanie M. Gallitano, Sameera Husain, Golnaz Moazami, Michael J. Weiss, and Catherine A. Shu
Opioid and Benzodiazepine Use in Women With Breast Cancer: More Work on the Horizon
Juan P. Cata and Daniel D. Kim
nausea, which is usually related to the administration of chemotherapy agents. Opioids and benzodiazepines are also prescribed simultaneously in patients with cancer. However, studies demonstrate that the concomitant prescription of opioids and
The Changing Paradigm of Treating Pancreatic Neuroendocrine Tumors
Renuka Iyer and Kaunteya Reddy
frequent adverse events were diarrhea, nausea, vomiting, asthenia, and fatigue. Median treatment duration was 4.6 months in the sunitinib group compared with 3.7 months in the placebo group. Median time from diagnosis was more than 2 years in both trials
The Changing Treatment Landscape for Metastatic Urothelial Carcinoma
Thomas W. Flaig
with chemotherapy (21% vs 11%). Most of the responses were in the first 6 months. The most common adverse reactions reported for at least 20% of pembrolizumab-treated patients included fatigue, musculoskeletal pain, pruritus, decreased appetite, nausea
NCCN News
; Adolescents and Young Adults With Cancer; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Distress; Hodgkin Lymphoma; Lung Cancer Screening; Malignant Pleural Mesothelioma; Melanoma; Multiple Myeloma; Myelodysplastic Syndromes; Nausea and Vomiting
Updates on the Management of Immunotherapy-Related Toxicities
Presented by: Marianne Davies, Jordan McPherson, and John A. Thompson
. Common toxicities include fatigue, pruritus, rash, nausea, and vomiting, but continuous monitoring for side effects is necessary throughout treatment, because specific irAEs may affect any organ system, are highly unpredictable, and vary in their timing
NCCN News
resources in parts of Africa. So far, the NCCN Harmonized Guidelines for Sub-Saharan Africa include: Adult Cancer Pain Antiemesis (nausea and vomiting prevention) B-Cell Lymphomas (Non-Hodgkin’s Lymphomas) Bladder Cancer Breast Cancer Cervical Cancer Chronic
NCCN News
includes >55 books for patients and caregivers covering most major types of cancer, along with topics like managing cancer-related distress, nausea and vomiting, and survivorship (both healthy living and cancer-related late and long-term effects), plus
NCCN News
part of the growing library that include 55 books for patients and caregivers from NCCN covering most major types of cancer, along with topics like managing cancer-related distress, nausea and vomiting, survivorship, and special considerations for
Additional Abstracts from the NCCN 21st Annual Conference: Advancing the Standard of Cancer Care™
cisplatin's high emetogenic potential, chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients with appropriate antiemetic regimens. Antiemetic guidelines recommend that patients treated with cisplatin should receive a combination